DHR Stock Analysis — Danaher Corporation
Sector: Healthcare
AI Verdict
Danaher trades at 20.4x next year's earnings while analysts expect nearly 90% EPS growth—cheap for the growth on offer if its operational moat and integration model deliver as expected.
Competitive Moat
Danaher operates a portfolio of specialized life sciences and diagnostics businesses, with a defensible edge from its proprietary technologies and recurring consumables revenue streams. Its Danaher Business System (DBS) creates operational efficiency and integration advantages that are hard for competitors to replicate.
Summary
Danaher is on watch as analysts expect earnings to nearly double next year, with a forward EPS growth estimate of 88.4%.
Where It Stands
Despite a 1-year return of -2.83% and an RSI of 71.8 signaling overbought territory, Danaher trades at 20.4x next year's earnings—below the healthcare sector median of 22x.
Key Metrics
- RSI: 71.8 — Overbought
- Trailing P/E: 38.5x
- Forward P/E: 20.4x
- PEG Ratio: 0.44
- Earnings Growth: +0.9%
- Revenue Growth: +0.0%
- Market Cap: $140.9B
- Dividend Yield: 0.01%
- 1-Year Return: -2.83%
- 52-Week High: $242.80
- 52-Week Low: $160.93
Analyst Consensus
27 Buy · 5 Hold · 0 Sell (32 analysts)
Bull Case
The forward P/E of 20.4x looks cheap for 88.4% expected EPS growth, especially with a trailing PEG of 0.44 indicating the growth more than justifies the multiple.
Bear Case
With an RSI of 71.8, a pullback could easily erase recent gains, and if the forward P/E reverts to the trailing 38.5x, it would imply a sharp rerating if growth disappoints.
Catalyst to Watch
Watch for quarterly earnings to confirm whether the forecasted 88.4% EPS growth materializes, as any miss could trigger a sharp correction given the overbought RSI.